Mednet Logo
CommunityEndocrinology

Would you add romosozumab to denosumab for a year or switch to romosozumab for a year in a patient who fractures on long term denosumab therapy?

1 Answer
Mednet Member
Mednet MemberInvited Expert
Rheumatology · Icahn School of Medicine at Mount Sinai
Answered on
  • My preference, if insurance were not an obstacle, would be to add romosozumab (Romo) rather than switch. The data are limited, and certainly this is "off-label," but the rationale is reasonable. Denosumab (Dmab) treatment leads to increased sclerostin levels which would be targeted by the addition ...

Join for free or sign in to see the full answer